Metagenomi Announces Name Change to Metagenomi Therapeutics, Inc. and Highlights Recent Progress in Hemophilia A Program and 2026 Outlook

Metagenomi Therapeutics, Inc. has announced a corporate name change to reflect its strategic evolution focused on later-stage preclinical assets. The company has completed a pre-IND meeting for MGX-001, its lead hemophilia A program, and anticipates IND/CTA submissions in 4Q 2026. MGX-001 demonstrated curative FVIII activity in non-human primates with no identifiable off-target editing. The company has a cash runway anticipated through 4Q 2027.